HK Stock Market Move | Some concept stocks of innovative drugs rose in early trading, with many rare disease drugs included in the medical insurance directory and commercial insurance innovative drug directory.

Some concept stocks of innovative drugs rose in early trading. As of the time of writing, JW THERAP-B (02126) rose by 8.77% to HK$3.35; CARSGEN-B (02171) rose by 3.8% to HK$18.87; CANBRIDGE-B (01228) rose by 3.38% to HK$2.45; JUNSHI BIO (01877) rose by 2.29% to HK$24.1. In terms of news, the drug list for the national basic medical insurance, maternity insurance, and work-related injury insurance in 2025 is the 8th adjustment since the establishment of the National Medical Insurance Bureau. This adjustment added 114 new drugs to the list, with 50 of them being type 1 innovative drugs. According to Caixin report, Shanghai Fosun Pharmaceutical's Luvotrivir tablets have been included in the 2025 medical insurance list, and Beihai Kangcheng's injection of Vira-amylase has been included in the commercial insurance innovative drug list. It is worth noting that the highly anticipated million-dollar CAR-T cell therapy, Fosun Kite's Axicabtagene Ciloleucel injection, WuXi's Razumabtagene Ciloleucel injection, Greatland Bio's Nagibatabtagene Ciloleucel injection, Sequis Biologics' Ixibatabtagene Ciloleucel injection, and Kyceed Life Sciences' Zivocibatabtagene Ciloleucel injection are all included in the first batch of commercial insurance innovative drug list.